FDAnews Drug Daily Bulletin

Sanofi Declines to Refund Philippine Dengvaxia Costs

Feb. 9, 2018

Sanofi shot down a demand from the Philippine Department of Health to refund the government approximately $58 million it paid for the now used doses of anti-dengue vaccine Dengvaxia.

The government’s demand came shortly after a Philippine task force reported the vaccine might be linked to three deaths.

“Agreeing to refund the used doses of Dengvaxia would imply that the vaccine is ineffective, which is not the case,” Sanofi said, according to a local news report.

View today's stories